205 related articles for article (PubMed ID: 28872228)
21. Tenosynovitis Induced by an Immune Checkpoint Inhibitor: A Case Report and Literature Review.
Murakami S; Nagano T; Nakata K; Onishi A; Umezawa K; Katsurada N; Yamamoto M; Tachihara M; Kobayashi K; Nishimura Y
Intern Med; 2019 Oct; 58(19):2839-2843. PubMed ID: 31243239
[TBL] [Abstract][Full Text] [Related]
22. Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?
Goldstein DA; Bilal U; Prasad V
Cancer; 2017 Oct; 123(20):3872-3874. PubMed ID: 28662268
[No Abstract] [Full Text] [Related]
23. An Unusual Case of Synchronous Metastatic Melanomas With Differing Response to Pembrolizumab.
Doolan BJ; McLean C; Mar V; Moore M
J Oncol Pract; 2019 Mar; 15(3):159-160. PubMed ID: 30861362
[No Abstract] [Full Text] [Related]
24. Pembrolizumab as second-line treatment for urothelial cancer.
Mitchell F
Lancet Oncol; 2017 Apr; 18(4):e197. PubMed ID: 28238595
[No Abstract] [Full Text] [Related]
25. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
[No Abstract] [Full Text] [Related]
26. Pembrolizumab as first line treatment of Merkel cell carcinoma patients - a case series of patients with various co-morbidities.
Bystrup Boyles T; Schødt M; Hendel HW; Krarup-Hansen A; Junker N
Acta Oncol; 2020 Jul; 59(7):793-796. PubMed ID: 32285728
[No Abstract] [Full Text] [Related]
27. Hepatobiliary and Pancreatic: Biliary injury related to checkpoint inhibitor "pembrolizumab".
Kida A; Matsuda K; Matsuda M; Sakai A
J Gastroenterol Hepatol; 2019 Sep; 34(9):1478. PubMed ID: 31197882
[No Abstract] [Full Text] [Related]
28. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet?
Rammohan A; Reddy MS; Farouk M; Vargese J; Rela M
Hepatology; 2018 Mar; 67(3):1166-1168. PubMed ID: 29023959
[No Abstract] [Full Text] [Related]
29. Pembrolizumab-Induced Rhabdomyolysis With Myositis in a Patient With Lung Adenocarcinoma.
Hamada S; Fuseya Y; Tsukino M
Arch Bronconeumol (Engl Ed); 2018 Jun; 54(6):346-348. PubMed ID: 29496287
[No Abstract] [Full Text] [Related]
30. Onychomadesis following pembrolizumab treatment for metastatic urothelial carcinoma: A report of two cases.
Sugihara Y; Kawai T; Yamada D; Furuyama C; Sato Y; Kume H
Eur J Cancer; 2020 Feb; 126():91-92. PubMed ID: 31923731
[No Abstract] [Full Text] [Related]
31. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases.
Jespersen H; Bjursten S; Ny L; Levin M
Lancet Oncol; 2018 Jun; 19(6):e327. PubMed ID: 29893264
[No Abstract] [Full Text] [Related]
32. A case of recurrent thrombocytopenia involving divergent immune-related mechanisms associated with pembrolizumab.
Matsumoto S; Kijima T; Matsuoka Y; Yamamoto M; Fujii Y
Eur J Cancer; 2020 May; 131():104-107. PubMed ID: 32234272
[No Abstract] [Full Text] [Related]
33. Making precision oncology the standard of care.
The Lancet Oncology
Lancet Oncol; 2017 Jul; 18(7):835. PubMed ID: 28677559
[No Abstract] [Full Text] [Related]
34. Pembrolizumab induced severe sclerodermoid reaction.
Shenoy N; Esplin B; Barbosa N; Wieland C; Thanarajasingam U; Markovic S
Ann Oncol; 2017 Feb; 28(2):432-433. PubMed ID: 27742656
[No Abstract] [Full Text] [Related]
35. Pembrolizumab-Induced Microscopic Colitis.
Ahmed M; Francis G
Am J Gastroenterol; 2018 Apr; 113(4):629-630. PubMed ID: 29610496
[No Abstract] [Full Text] [Related]
36. Pembrolizumab induced acute corneal toxicity after allogeneic stem cell transplantation.
Hsiao CC; Yao M; Liu JH; Chen WL
Clin Exp Ophthalmol; 2018 Aug; 46(6):698-700. PubMed ID: 29280537
[No Abstract] [Full Text] [Related]
37. Corneal melting in a case undergoing treatment with pembrolizumab.
Weng CC; Wu CC; Lin PY
Clin Exp Optom; 2020 May; 103(3):379-381. PubMed ID: 31692096
[No Abstract] [Full Text] [Related]
38. Pembrolizumab-Induced Pancytopenia: A Case Report.
Atwal D; Joshi KP; Ravilla R; Mahmoud F
Perm J; 2017; 21():17-004. PubMed ID: 28746020
[TBL] [Abstract][Full Text] [Related]
39. Three more immune checkpoint inhibitors for advanced bladder cancer.
Med Lett Drugs Ther; 2017 Dec; 59(1535):e202-e203. PubMed ID: 29186087
[No Abstract] [Full Text] [Related]
40. Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab.
Owosho AA; Randazzo J; Rosen EB; Estilo CL; Huryn JM; Chi P; Yom SK
Oral Oncol; 2016 Dec; 63():e1-e3. PubMed ID: 27743938
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
